Patent classifications
C12N5/54
NON-FREEZING REFRIGERATED STORAGE LIQUID AND STORAGE METHOD FOR STEM CELLS
Provided are a cold storage method and a cold storage liquid that are suitable for non-freezing refrigerated storage of human or animal stem cells such as iPS cells or embryos in a non-frozen state. According to an embodiment, the non-freezing refrigerated storage liquid is: a mixture liquid (HTM, HTMx2c13), in which MEM-alpha (Minimum Essential Medium Eagle (MEM) Alpha Modification) is mixed with a UW solution (UW_sln; BELZER UW (registered trademark) COLD STORAGE SOLUTION), or a modified UW solution (polymer component being changed to PVA), are mixed in a ratio of about 1/1 to 1/2; or a storage liquid having a composition equivalent to the mixture liquid, especially in respect of concentrations of potassium ions and sodium ions. And, arousal period(s) of maintaining a temperature of 30 C. to 37 C. is inserted at each of two to five days, into a non-freezing refrigerated storage period, which is made at 2 C. to 8 C. for 2 to 10 days or 4 to 20 days.
PROCESS FOR PREPARATION AND CRYOPRESERVATION OF DENTAL PULP FROM DEFINITIVE TEETH AND PRODUCTS THEREOF BASED ON ISOLATED MESENCHYMAL STEM CELLS
The present invention relates to a process for preparation and cryopreservation of dental pulp teeth and products thereof resulting in innovative cellular systems useful for therapeutic application based on the mesenchymal stem cells, so called dental pulp stem cells (DPSCs).
The objective of this invention is to provide the most adequate cellular isolates from dental pulp tissue from a tooth of a human subject. Fast expanding populations of DPSCs can be obtained, while maintaining their chromosomal stability, and determined to present the phenotypical and functional characteristics desired of such populations.
In another aspect, the present invention provides a novel and simplified method increasing thSpece viability of the dental tissue during the storing and banking. Also, the isolation of DPSCs from these teeth is improved and herein disclosed.
Therefore, the present invention is in the field of cell-based therapies, regenerative medicine, and optimized processes for obtaining the desired cell-isolates.